Clinical trial / 2011
Dietary supplementation with vitamin E significantly increased the risk of prostate cancer in healthy men.
The SELECT trial randomized 34,887 men to receive selenium (200 μg/d), vitamin E (400 IU/d), both, or placebo to assess prostate cancer risk. Compared to placebo (529 cases), 620 men receiving vitamin E developed prostate cancer (HR 1.17; 99% CI, 1.004-1.36; P = .008), corresponding to an absolute increase of 1.6 cases per 1000 person-years. Prostate cancer cases were 575 in the selenium group (HR 1.09; 99% CI, 0.93-1.27; P = .18) and 555 in the combination group (HR 1.05; 99% CI, 0.89-1.22; P = .46).
- Study type
- Randomized controlled trial
- Who was studied
- 34,887 relatively healthy men aged 50+ (Black) or 55+ (all others)
- What was measured
- Prostate cancer incidence
THE PAPER
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. JAMA, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.